Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Oct 1;31(4):2289–2302. doi: 10.1007/s00330-020-07303-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — a, b A 47-year-old woman with a 5.2-cm poorly differentiated LR-5 HCC in hepatic segment VI and serum AFP level of 1.38 ng/mL. a Mass shows non-rim hyperenhancement, nodule-in-nodule (asterisk), and mosaic architecture on late arterial phase. b Mass shows mixed intensity and peritumoral hypointensity (arrowhead) on hepatobiliary phase (HBP). This patient had one of the predictive MR imaging findings (peritumoral hypointensity on HBP) for early recurrence and was categorized as LR-5b. Early recurrence occurred in the liver during follow-up after curative resection. The disease-free survival was 23.7 months. c, d A 29-year-old man with a 7.0-cm moderately differentiated LR-5 HCC in hepatic segment VI and the serum AFP level was higher than 1210 ng/mL. c Mass shows non-rim hyperenhancement, nodule-in-nodule (asterisk), mosaic architecture, and corona enhancement (arrowhead) on late arterial phase. d Mass shows hypointensity and non-smooth tumor margin on hepatobiliary phase. This patient had one of the predictive MR imaging findings (corona enhancement) for early recurrence and was categorized as LR-5b. Early recurrence occurred in the liver during follow-up after curative resection. The disease-free survival was 8.5 months